The ups and downs of novel antiemetic drugs, part 2: an illustration.
Novel antiemetic drugs block either neurokinin-1 receptors or serotonin-3 receptors. Research into the neuropharmacology of vomiting is providing insight into the ways substance P and serotonin interact within the central nervous system that could lead to additional applications of neurokinin-1 antagonists for the treatment of depression and stress.
Stahl
Stephen M
SM
Neuroscience Education Institute in Carlsbad, Calif., and the Department of Psychiatry at the University of California San Diego, CA92009, USA.
D000932:Antiemetics / Q000494:pharmacology*; D001933:Brain Stem / Q000187:drug effects* / Q000502:physiology; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D008959:Models, Neurological; D064729:Neurokinin-1 Receptor Antagonists; D011985:Receptors, Serotonin / Q000187:drug effects*; D044406:Receptors, Serotonin, 5-HT3; D012701:Serotonin / Q000502:physiology; D040921:Stress Disorders, Traumatic / Q000188:drug therapy; D013373:Substance P / Q000037:antagonists & inhibitors / Q000502:physiology; D014839:Vomiting / Q000503:physiopathology / Q000517:prevention & control*
D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists; D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D012701:Serotonin; D013373:Substance P